Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark

Citations

Cited by:

1. Bardey, David & Harker, Arturo & Zuluaga, Daniela, 2021. "Price cap regulation in the Colombian pharmaceutical market: An impact evaluation," TSE Working Papers 21-1195, Toulouse School of Economics (TSE).
   • David Bardey & Arturo Harker & Daniela Zuluaga, 2021. "Price cap regulation in the Colombian pharmaceutical market: An impact evaluation," Documentos CEDE 19117, Universidad de los Andes, Facultad de Economía, CEDE.
2. Herr, A. & Suppliet, M., 2011. "Co-Payment Exemptions and Reference Prices: an Empirical Study of Pharmaceutical Prices in Germany," Health, Econometrics and Data Group (HEDG) Working Papers 11/18, HEDG, c/o Department of Economics, University of York.
   • Herr, Annika & Suppliet, Moritz, 2012. "Pharmaceutical prices under regulation: Tiered co-payments and reference pricing in Germany," DICE Discussion Papers 48, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
   • Suppliet, Moritz & Herr, Annika, 2016. "Cost-Sharing and Drug Pricing Strategies : Introducing Tiered Co-Payments in Reference Price Markets," Discussion Paper 2016-021, Tilburg University, Tilburg Law and Economic Center.
   • Suppliet, Moritz & Herr, Annika, 2016. "Cost-Sharing and Drug Pricing Strategies : Introducing Tiered Co-Payments in Reference Price Markets," Discussion Paper 2016-040, Tilburg University, Center for Economic Research.
3. Susan J. Méndez, 2018. "Parallel trade of pharmaceuticals: The Danish market for statins," Health Economics, John Wiley & Sons, Ltd., vol. 27(2), pages 333-356, February.
   • Susan J. Méndez, 2016. "Parallel Trade of Pharmaceuticals: The Danish Market for Statins," Melbourne Institute Working Paper Series wp2016n08, Melbourne Institute of Applied Economic and Social Research, The University of Melbourne.
4. Mats A. Bergman & David Granlund & Niklas Rudholm, 2016. "Reforming the Swedish pharmaceuticals market: consequences for costs per defined daily dose," International Journal of Health Economics and Management, Springer, vol. 16(3), pages 201-214, September.
5. Annika Herr & Torben Stühmeier & Tobias Wenzel, 2023. "More cost‐sharing, less cost? Evidence on reference price drugs," Health Economics, John Wiley & Sons, Ltd., vol. 32(2), pages 413-435, February.
6. Suppliet, Moritz & Herr, Annika, 2016. "Cost-Sharing and Drug Pricing Strategies : Introducing Tiered Co-Payments in Reference Price Markets," Other publications TiSEM 4d692f0e-8577-4392-b413-2, Tilburg University, School of Economics and Management.
   • Suppliet, Moritz & Herr, Annika, 2016. "Cost-Sharing and Drug Pricing Strategies : Introducing Tiered Co-Payments in Reference Price Markets," Other publications TiSEM 6430293b-fde9-4f91-ab35-3, Tilburg University, School of Economics and Management.
   • Suppliet, Moritz & Herr, Annika, 2016. "Cost-Sharing and Drug Pricing Strategies : Introducing Tiered Co-Payments in Reference Price Markets," Discussion Paper 2016-021, Tilburg University, Tilburg Law and Economic Center.
   • Suppliet, Moritz & Herr, Annika, 2016. "Cost-Sharing and Drug Pricing Strategies : Introducing Tiered Co-Payments in Reference Price Markets," Discussion Paper 2016-040, Tilburg University, Center for Economic Research.
7. Kurt R. Brekke & Chiara Canta & Odd Rune StraumeAuthor-Email: o.r.straume@eeg.uminho.p, 2015. "Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform," NIPE Working Papers 6/2015, NIPE - Universidade do Minho.
   • Kurt R. Brekke & Chiara Canta & Odd Rune Straume, 2022. "Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform," CESifo Working Paper Series 9853, CESifo.
   • Brekke, Kurt R. & Canta, Chiara & Straume, Odd Rune, 2015. "Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform," Discussion Paper Series in Economics 11/2015, Norwegian School of Economics, Department of Economics.
8. David Granlund & Miyase Koksal-Ayhan, 2015. "Parallel imports and a mandatory substitution reform: a kick or a muff for price competition in pharmaceuticals?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 969-983, December.
9. Eduardo Costa & Carolina Santos, 2022. "Pharmaceutical pricing dynamics in an internal reference pricing system: evidence from changing drugs’ reimbursements," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(9), pages 1497-1518, December.
10. Salgado Alfredo, 2022. "Regulation through Reference Prices," Working Papers 2022-05, Banco de México.
11. Skipper, Niels & Vejlin, Rune, 2015. "Determinants of generic vs. brand drug choice: Evidence from population-wide Danish data," Social Science & Medicine, Elsevier, vol. 130(C), pages 204-215.
    • Niels Skipper & Rune Vejlin, 2013. "Determinants of Generic vs. Brand Drug Choice: Evidence from Population-wide Danish Data," Economics Working Papers 2013-05, Department of Economics and Business Economics, Aarhus University.
12. Gregory J. Critchley & Gregory S. Zaric, 2019. "The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare," Health Economics, John Wiley & Sons, Ltd., vol. 28(8), pages 1035-1051, August.
13. Brekke, Kurt R. & Canta, Chiara & Straume, Odd Rune, 2016. "Reference pricing with endogenous generic entry," Journal of Health Economics, Elsevier, vol. 50(C), pages 312-329.
    • Kurt R. Brekke & Chiara Canta & Odd Rune Straume, 2015. "Reference pricing with endogenous generic entry," NIPE Working Papers 2/2015, NIPE - Universidade do Minho.
    • Brekke, Kurt R. & Canta, Chiara & Straume, Odd Rune, 2015. "Reference pricing with endogenous generic entry," Discussion Paper Series in Economics 4/2015, Norwegian School of Economics, Department of Economics.
14. Birg, Laura, 2019. "Reference Pricing and Parallel Imports: Evidence from Germany," VfS Annual Conference 2019 (Leipzig): 30 Years after the Fall of the Berlin Wall - Democracy and Market Economy 203666, Verein für Socialpolitik / German Economic Association.
    • Birg, Laura, 2019. "Reference pricing and parallel imports: Evidence from Germany," University of Göttingen Working Papers in Economics 362, University of Goettingen, Department of Economics.
15. Suppliet, Moritz, 2020. "Umbrella branding in pharmaceutical markets," Journal of Health Economics, Elsevier, vol. 73(C).
    • Suppliet, Moritz, 2017. "Umbrella Branding in Pharmaceutical Markets," Other publications TiSEM 6ee607fc-8602-4270-a076-3, Tilburg University, School of Economics and Management.
    • Suppliet, Moritz, 2017. "Umbrella Branding in Pharmaceutical Markets," Discussion Paper 2017-033, Tilburg University, Center for Economic Research.
    • Suppliet, Moritz, 2017. "Umbrella Branding in Pharmaceutical Markets," Discussion Paper 2017-034, Tilburg University, Tilburg Law and Economic Center.
    • Suppliet, Moritz, 2017. "Umbrella Branding in Pharmaceutical Markets," Other publications TiSEM be3f3c38-5e39-4a67-af57-8, Tilburg University, School of Economics and Management.
16. Foad Iravani & Hamed Mamani & Emisa Nategh, 2020. "External Reference Pricing and Parallel Imports of Pharmaceuticals: A Policy Comparison," Production and Operations Management, Production and Operations Management Society, vol. 29(12), pages 2716-2735, December.
17. Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune, 2011. "Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment," Journal of Public Economics, Elsevier, vol. 95(7), pages 624-638.
    • Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune, 2011. "Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment," Journal of Public Economics, Elsevier, vol. 95(7-8), pages 624-638, August.
    • Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume, 2010. "Reference Pricing, Competition, and Pharmaceutical Expenditures: Theory and Evidence from a Natural Experiment," CESifo Working Paper Series 3258, CESifo.
18. Sebastian Linde & Brandon Norton & Ralph Siebert, 2019. "The Effect of Bargaining Power Determinants on Pharmaceutical Prices," CESifo Working Paper Series 7988, CESifo.
19. Markkanen, Jaakko, 2024. "Passthrough of Retail Price Regulation in the Market for Pharmaceuticals," ETLA Working Papers 123, The Research Institute of the Finnish Economy.
20. Tomaso Duso & Annika Herr & Moritz Suppliet, 2014. "The Welfare Impact Of Parallel Imports: A Structural Approach Applied To The German Market For Oral Anti‐Diabetics," Health Economics, John Wiley & Sons, Ltd., vol. 23(9), pages 1036-1057, September.
    • Suppliet, Moritz & Duso, Tomaso & Herr, Annika, 2014. "The welfare impact of parallel imports: A structural approach applied to the German market for oral antidiabetics," VfS Annual Conference 2014 (Hamburg): Evidence-based Economic Policy 100298, Verein für Socialpolitik / German Economic Association.
    • Duso, T. & Herr, A. & Suppliet, M, 2014. "The Welfare Impact of Parallel Imports: A Structural Approach Applied to the German Market for Oral Anti-diabetics," Health, Econometrics and Data Group (HEDG) Working Papers 14/09, HEDG, c/o Department of Economics, University of York.
    • Tomaso Duso & Annika Herr & Moritz Suppliet, 2014. "The Welfare Impact of Parallel Imports: A Structural Approach Applied to the German Market for Oral Anti-Diabetics," Discussion Papers of DIW Berlin 1373, DIW Berlin, German Institute for Economic Research.
    • Duso, Tomaso & Herr, Annika & Suppliet, Moritz, 2014. "The welfare impact of parallel imports: A structural approach applied to the German market for oral anti-diabetics," DICE Discussion Papers 137, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
21. Hauschultz, Frederik Plum & Munk-Nielsen, Anders, 2020. "Markups on Drop-Downs: Prominence in Pharmaceutical Markets∗," MPRA Paper 104582, University Library of Munich, Germany.
22. repec:iae:iaewps:wp2016n8 is not listed on IDEAS
23. Ivan Moreno-Torres, 2011. "What if there was a stronger pharmaceutical price competition in Spain? When regulation has a similar effect to collusion," Working Papers XREAP2011-02, Xarxa de Referència en Economia Aplicada (XREAP), revised May 2011.
24. Kaiser, Ulrich & Méndez, Susan J., 2015. "How Do Drug Prices Respond to a Change from External to Internal Reference Pricing? Evidence from a Danish Regulatory Reform," IZA Discussion Papers 8759, Institute of Labor Economics (IZA).
    • Kaiser, Ulrich & Mendez, Susan J., 2015. "How do drug prices respond to a change from external to internal reference pricing? Evidence from a Danish regulatory reform," ZEW Discussion Papers 15-004, ZEW - Leibniz Centre for European Economic Research.
    • Ulrich Kaiser & Susan J. Méndez, 2015. "How Do Drug Prices Respond to a Change from External to Internal Reference Pricing? Evidence from a Danish Regulatory Reform," Melbourne Institute Working Paper Series wp2015n04, Melbourne Institute of Applied Economic and Social Research, The University of Melbourne.
25. Jun Li & Di (Andrew) Wu, 2022. "The Price Effect of Drug Price Ceilings: Intended and Unintended Consequences," Management Science, INFORMS, vol. 68(8), pages 5758-5777, August.
26. Joosse, Iris R. & Tordrup, David & Bero, Lisa & Mantel-Teeuwisse, Aukje K. & van den Ham, Hendrika A., 2023. "A critical review of methodologies used in pharmaceutical pricing policy analyses," Health Policy, Elsevier, vol. 134(C).
27. Timothy T. Brown & James C. Robinson, 2016. "Reference Pricing with Endogenous or Exogenous Payment Limits: Impacts on Insurer and Consumer Spending," Health Economics, John Wiley & Sons, Ltd., vol. 25(6), pages 740-749, June.
28. repec:nip:nipewp:06/2015 is not listed on IDEAS
29. Alfredo Salgado-Torres, 2024. "Regulation through reference prices/Regulación a través de precios de referencia," Estudios Económicos, El Colegio de México, Centro de Estudios Económicos, vol. 39(1), pages 159-201.
30. J. M. C. Santos Silva & Silvana Tenreyro, 2022. "The Log of Gravity at 15," Portuguese Economic Journal, Springer;Instituto Superior de Economia e Gestao, vol. 21(3), pages 423-437, September.
    • J.M.C. Santos Silva & Silvana Tenreyro, 2021. "The Log of Gravity At 15," School of Economics Discussion Papers 0121, School of Economics, University of Surrey.
    • Silva, J.M.C. Santos & Tenreyo, Silvana, 2022. "The Log of Gravity at 15," LSE Research Online Documents on Economics 112437, London School of Economics and Political Science, LSE Library.
31. Ivan Moreno-Torres, 2011. "Generic drugs in Spain: price competition vs. moral hazard," Working Papers XREAP2011-04, Xarxa de Referència en Economia Aplicada (XREAP), revised May 2011.
32. Dominik J. Wettstein & Stefan Boes, 2019. "Effectiveness of National Pricing Policies for Patent-Protected Pharmaceuticals in the OECD: A Systematic Literature Review," Applied Health Economics and Health Policy, Springer, vol. 17(2), pages 143-162, April.
33. Koenig, Pamina & MacGarvie, Megan, 2011. "Regulatory policy and the location of bio-pharmaceutical foreign direct investment in Europe," Journal of Health Economics, Elsevier, vol. 30(5), pages 950-965.
    • Pamina Koenig & Megan Macgarvie, 2011. "Regulatory policy and the location of bio-pharmaceutical foreign direct investment in Europe," Post-Print halshs-00754522, HAL.
    • Pamina Koenig & Megan Macgarvie, 2011. "Regulatory policy and the location of bio-pharmaceutical foreign direct investment in Europe," PSE-Ecole d'économie de Paris (Postprint) halshs-00754522, HAL.
34. Nazila Yousefi & Mahyar Polroudi Moghaddam & Gita Afsharmanesh & Farzad Peiravian, 2020. "Evaluation of efficiency enhancement in Iran Health Insurance Organization: a policy brief for pharmaceutical cost containment," International Journal of Health Planning and Management, Wiley Blackwell, vol. 35(6), pages 1503-1511, November.
35. Toon van der Gronde & Carin A Uyl-de Groot & Toine Pieters, 2017. "Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks," PLOS ONE, Public Library of Science, vol. 12(8), pages 1-34, August.
36. Stadhouders, Niek & Kruse, Florien & Tanke, Marit & Koolman, Xander & Jeurissen, Patrick, 2019. "Effective healthcare cost-containment policies: A systematic review," Health Policy, Elsevier, vol. 123(1), pages 71-79.
37. Herr, Annika & Stühmeier, Torben & Wenzel, Tobias, 2014. "Reference pricing and cost-sharing: Theory and evidence on German off-patent drugs," VfS Annual Conference 2014 (Hamburg): Evidence-based Economic Policy 100556, Verein für Socialpolitik / German Economic Association.